SOURCE: Paragon Financial Limited

Paragon Financial Limited

November 22, 2012 08:20 ET

Medical Device Excise Tax to Have a Significant Impact on Industry Profits in the New Year

The Paragon Report Provides Stock Research on St. Jude Medical and Sunshine Heart

NEW YORK, NY--(Marketwire - Nov 22, 2012) - The Medical Devices Industry has shown admirable gains in 2012, but a medical device excise tax set to kick in next year will have a major impact on companies' profits going forward. The iShares Dow Jones US Medical Devices ETF (IHI) has gained nearly 20 percent year-to-date. The Paragon Report examines investing opportunities in the Medical Equipment and Supplies Industry and provides equity research on St. Jude Medical, Inc. (NYSE: STJ) and Sunshine Heart Inc. (NASDAQ: SSH).

Access to the full company reports can be found at:

www.ParagonReport.com/STJ

www.ParagonReport.com/SSH

The medical device excise tax, which was designed to support the Affordable Care Act, places a 2.3 percent levy on all sales of medical devices regardless if a company makes a profit or not. Despite not taking effect until January 1, 2013, many companies have already announced job cuts and delayed expansion plans in preparation for the tax.

"American already has the highest corporate tax rates in the world," AdvaMed senior executive vice president David Nexon told reporters today. "To load this additional burden on an industry which is so important to our economy and which is facing a strong international competitive pressure makes no sense at all; it flies in the face of everything tax reform is supposed to achieve."

Paragon Report releases regular market updates on the Medical Equipment and Supplies Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. Shares of the company fell sharply Wednesday after an inspection report from the FDA found serious flaws in the company's design changes to their Durata line of implantable defibrillator leads.

Sunshine Heart is an early-stage global medical device company committed to the commercialization of the C-Pulse Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure. Shares of the company spiked earlier this week after reporting it has received unconditional approval from the FDA to begin trials of their C-Pulse Heart Assist System.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer